Ondine Biomedical Inc (AIM:OBI, OTC:OBIMF), a specialist in light-activated antimicrobial treatments, said its commercial progress so far this year has been ahead of management's expectations, buoyed by the deployment of its Steriwave technology in eight new healthcare facilities.
It brings the total number of hospitals using Steriwave to 22, nearly quadruple the number a year ago.
The Ottawa Hospital (TOH) is increasing its utilisation of Steriwave, extending its application from spinal to orthopaedic and vascular surgeries, anticipating its use in approximately 2,600 surgical procedures annually — a threefold increase from its pilot phase.
This decision follows a comprehensive cost-benefit analysis, highlighting Steriwave's effectiveness in reducing post-surgical infection rates and associated healthcare costs.
In addition to the domestic expansion, Ondine's international footprint is growing, with the first three hospitals in Spain, including Hospital Universitario La Paz (HULP) in Madrid, initiating a paid pilot on the Ondine technology.
This development is part of a strategy to address the rising global challenge of antibiotic resistance and the associated healthcare costs, as evidenced by recent findings showing a net saving of nearly C$2,600 per spine surgery patient treated with Steriwave and chlorhexidine skin decolonisation.
The expansion also includes the Sturgeon Community Hospital in Alberta, part of Canada's largest integrated health system, and the Nanaimo Regional General Hospital in British Columbia.
Both institutions have adopted Steriwave to reduce surgical site infections (SSIs) in various surgical procedures, further demonstrating the technology's applicability and efficacy across different medical specialties.
Ondine Biomedical is currently engaging with medical device distributors to broaden Steriwave's commercial reach.